Anti-microbial/Anti-fungal Tests Market Research Report 2022 to 2032
By the end of 2022, the market for anti-microbial/anti-fungal tests is anticipated to be worth US$2.5 Bn. By 2032, the market is expected to grow at a CAGR of 5.7% and surpass US$ 4.5 billion. According to test type, molecular-based tests held the market lead in 2021 with a share of just under 53.5%.
Microbial and fungal infections are a major cause of death
globally and can even cause potential epidemics, creating a huge economic
burden on countries, especially developing ones. To nip the spread of such
infections in the bud, prevention is a far better solution than cure –
accomplished by isolating infected cases and carrying out primary screening
tests. Future Market Insights in its report titled ‘Anti-microbial/Anti-fungal
Tests Market: Global Industry Analysis 2012–2016 and Opportunity Assessment
2017–2027’ has comprehensively analysed the
global anti-microbial/ anti-fungal tests market for a decade. The
anti-microbial/ anti-fungal tests market is expected to witness a robust CAGR
of 6% from 2017 to 2027.
Request for a sample @
https://www.futuremarketinsights.com/reports/sample/rep-gb-5566
Region – Robust Healthcare Infrastructure in North
America Enables Rapid Anti-Microbial/ Anti-Fungal Testing
North America has the largest regional contribution and is
predicted to account for approx. a third of the anti-microbial/ anti-fungal
tests market at the end of the forecast period. The North America
anti-microbial/ anti-fungal tests market should cross a billion dollars by 2027
– the only region to do so. Most physicians on the continent typically
prescribe diagnostics tests before starting any sort of treatment, fuelling
demand for anti-microbial/ anti-fungal test kits. Furthermore, there is immense
awareness of the side-effects of certain drugs and patients often prefer to get
completely diagnosed before seeking treatment.
Test Type – Molecular Based Tests Critical in
Anti-Microbial/ Anti-Fungal Tests Market
Molecular based tests dominated the global anti-microbial/
anti-fungal tests market by test type in 2017 and are likely to retain this
commanding position for the foreseeable future. Molecular based tests have a
market attractiveness index of 2.6 – considerably higher than all other test
types in the anti-microbial/ anti-fungal tests market. Within the molecular
based tests segment, companies would be advised to focus their attention on the
PCR Test sub-segment as it is roughly thrice the size of DNA microarray tests
in terms of value. The PCR test segment is further poised to record a CAGR of
6.4% for the decadal study.
Infection Type – Target Antimicrobial Resistance and
Microbial Infection Segments in Anti-Microbial/ Anti-Fungal Tests Market
The antimicrobial and microbial resistance segments are the
ones to look out for as they comprise almost 3/4th of the
global anti-microbial/ anti-fungal tests market between them. The
multi-drug-resistant mycobacterium tuberculosis sub-segment is the largest in
the antimicrobial resistance segment and should grow at a high rate as well.
Along with multi-drug-resistant mycobacterium tuberculosis, the microbial
infection segment holds great potential in the anti-microbial/ anti-fungal
tests market as it is on track to push past a value of US$ 1 billion by end
2027.
Request Customization @
https://www.futuremarketinsights.com/customization-available/rep-gb-5566
End User – Hospitals and Reference Labs Demand
Antimicrobial/ Antifungal Testing Kits
Hospitals and reference labs are the largest end users in
the anti-microbial/ anti-fungal tests market by a substantial margin. It has
been observed that the global per-capita healthcare spending has doubled
because of rising awareness of myriad treatment options and diagnostic tools
for detecting and curing various diseases. Reference labs are predicted to grow
faster than hospitals in the anti-microbial/ anti-fungal tests market.
Competition Dashboard in the Anti-Microbial/ Anti-Fungal
Tests Market
The companies profiled in the report are Abbott
Laboratories, bioMérieux SA, Bio-Rad Laboratories, Bruker Corporation, Danaher
Corporation, Erba Mannheim, F. Hoffmann-La Roche AG, Luminex Corporation,
Meridian Bioscience, Norgen Biotek Corp., Omega Diagnostics Group Plc., Qiagen
N.V., Quidel Corporation, and Thermo Fisher Scientific Inc.
Takeaways
The prevalence and incidence rate of infectious diseases
such as diarrhoea and malaria is at an all-time high in Asia and Africa.
Governmental and non-governmental organizations such as the WHO are seeking to
reduce prevalence rates by early diagnosis through antimicrobial and antifungal
kits. In addition to this, government tenders and partnerships with
manufacturers is anticipated to provide a steady revenue stream for the latter,
growing the anti-microbial/ anti-fungal tests market as a whole.
Why Future Market Insights?
• Comprehensive analysis on evolving purchase pattern across
different geographies
• Detailed insights of market segments and sub-segments for historical as well
as forecast period
• A competitive analysis of prominent players and emerging players in the
keyword market
• Detailed information about the product innovation, mergers and acquisitions
lined up in upcoming years
Ground breaking research and market player-centric solutions
for the upcoming decade according to the present market scenario
Enquiry/Query @
https://www.futuremarketinsights.com/ask-question/rep-gb-5566
Key Market Segments Covered in Anti-microbial/Anti-fungal
Tests Industry Research
By Tests Type:
·
Molecular Based Tests
·
Phenotypic Resistance Tests
·
Rapid Diagnostic Tests
By Infection Type:
·
Antimicrobial Resistance
·
Carbapenem-Resistant Enterobacteriaceae gut
bacteria
·
Candida infections
By End User:
- Hospitals
- Ambulatory
Surgical Centers
- Clinics
- Community
Health Centers
- Reference
Laboratories
Full Report @https://www.futuremarketinsights.com/reports/anti-microbial-anti-fungal-tests-market
Comments
Post a Comment